Topic: safety accuracy concerns

OpenAI and FDA in Talks to Use AI for Drug Evaluations

The FDA is in talks with OpenAI and others to develop AI tools like **cderGPT** to speed up drug evaluations, potentially reducing approval timelines by years. AI could address bottlenecks in late-stage drug reviews, but challenges remain in ensuring accuracy and minimizing risks from algorithmic...